NCT01560416View on ClinicalTrials.gov

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant

DRUG

Ganetespib

Trial Locations (5)

27599

University of North Carolina, Chapel Hill

02130

DFCI at Faulkner Hospital, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

03301

New Hampshire Oncology and Hematology, P.A., Concord

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER